AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38702618 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 60
Study 38702619 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized education and home blood pressure monitoring
Number of subjects: 250
Study 38702654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) in low-risk group (≤ 1 risk factors)
Number of subjects: 274
Study 38702654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) in high-risk group (> 1 risk factors)
Number of subjects: 274
Study 38702744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-placed bronchial balloon
Number of subjects: 250
Study 38702744 — intervention group
Group type: COMPARATOR
Intervention: None-pre-placed bronchial balloon
Number of subjects: 250
Study 38702751 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum patient navigation program
Number of subjects: 11
Study 38702761 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) 36.25 Gy in 5 fractions to the whole prostate gland with MRI guided simultaneous integrated focal boost (SIB) to the index lesion (IL) up to 50 Gy in 5 fractions.
Number of subjects: 0
Study 38702761 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR with MRI guided focal dose intensification
Number of subjects: 0
Study 38702783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to MOUD
Number of subjects: 303
Study 38702786 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalized semi-parametric mixture cure model (MCM) using RNA-sequencing data
Number of subjects: 346
Study 38702786 — intervention group
Group type: EXPERIMENTAL
Intervention: Training set MCM
Number of subjects: 346
Study 38702786 — intervention group
Group type: EXPERIMENTAL
Intervention: Test set MCM
Number of subjects: 346
Study 38702828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant niraparib treatment
Number of subjects: 0
Study 38702828 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant platinum-taxane doublet chemotherapy
Number of subjects: 0
Study 38702961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium channel blockers (SCBs) - flecainide or propafenone
Number of subjects: 1395
Study 38703010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirogacestat (150 mg, twice-daily, continuous 28-day cycles)
Number of subjects: 73
Study 38703010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 38703010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirogacestat (150 mg)
Number of subjects: 73
Study 38703071 — intervention group
Group type: EXPERIMENTAL
Intervention: METsmeasured
Number of subjects: 98
Study 38703071 — intervention group
Group type: EXPERIMENTAL
Intervention: METsestimated
Number of subjects: 98
Study 38703071 — intervention group
Group type: EXPERIMENTAL
Intervention: V˙O2Reserve
Number of subjects: 98
Study 38703071 — intervention group
Group type: EXPERIMENTAL
Intervention: Current classification metrics
Number of subjects: 98
Study 38703097 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening presented as an opportunity
Number of subjects: 790
Study 38703097 — intervention group
Group type: COMPARATOR
Intervention: Screening presented as a choice
Number of subjects: 790
Study 38703097 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening presented as an opportunity plus a question about women's stage of decision making
Number of subjects: 790
Study 38703097 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no specific intervention)
Number of subjects: 790
Study 38703149 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-CTO score (moderate-severe calcification, tortuosity, Werner collateral connection grade ≤1, and nonseptal collateral channel)
Number of subjects: 2374
Study 38703149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower JR-CTO scores
Number of subjects: 2374
Study 38703279 — intervention group
Group type: EXPERIMENTAL
Intervention: NHFOV
Number of subjects: 100
Study 38703279 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 100
Study 38703336 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg AZD7442 (tixagevimab/cilgavimab) in PROVENT
Number of subjects: 6000
Study 38703336 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg AZD7442 (tixagevimab/cilgavimab) in STORM CHASER
Number of subjects: 6000
Study 38703336 — intervention group
Group type: COMPARATOR
Intervention: Placebo in PROVENT
Number of subjects: 6000
Study 38703336 — intervention group
Group type: COMPARATOR
Intervention: Placebo in STORM CHASER
Number of subjects: 6000
Study 38703375 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomorphic ventricular tachycardia (MMVT)
Number of subjects: 2668
Study 38703375 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic ventricular tachycardia (PVT)/ventricular fibrillation (VF)
Number of subjects: 2668
Study 38703375 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk Fine-Gray model for MMVT
Number of subjects: 2668
Study 38703782 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoculation with SARS-CoV-2 in a stepwise dose escalation controlled human infection model (CHIM) with a dose of 1×10
Number of subjects: 36
Study 38703890 — intervention group
Group type: EXPERIMENTAL
Intervention: High Eating Frequency (6 eating occasions/d)
Number of subjects: 50
Study 38703890 — intervention group
Group type: COMPARATOR
Intervention: Low Eating Frequency (3 eating occasions/d)
Number of subjects: 50
Study 38703993 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-approved anti-angiogenic agents combined with immunotherapy and nanocarrier-mediated targeted therapy
Number of subjects: 0
Study 38704119 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard educational materials combined with web-based decision support tools
Number of subjects: 415
Study 38704119 — intervention group
Group type: COMPARATOR
Intervention: Standard educational materials alone
Number of subjects: 415
Study 38704288 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 98
Study 38704288 — intervention group
Group type: EXPERIMENTAL
Intervention: KardiaMobile 6L
Number of subjects: 98
Study 38704288 — intervention group
Group type: COMPARATOR
Intervention: 12L-ECG
Number of subjects: 98
Study 38704294 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB/AML 150/5 mg
Number of subjects: 428
Study 38704294 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB/AML 150/10 mg
Number of subjects: 428
Study 38704294 — intervention group
Group type: COMPARATOR
Intervention: IRB 150 mg/placebo
Number of subjects: 428
Study 38704294 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB/AML 300/5 mg
Number of subjects: 428
Study 38704294 — intervention group
Group type: COMPARATOR
Intervention: IRB 300 mg/placebo
Number of subjects: 428
Study 38704329 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Esteem Development Programme (8 sessions, 45-60 min each, one session per week)
Number of subjects: 66
Study 38704329 — intervention group
Group type: COMPARATOR
Intervention: Routine education programme (control group)
Number of subjects: 66
Study 38704414 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training for twelve weeks (n=14)
Number of subjects: 30
Study 38704414 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 30
Study 38704501 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan/Hepatic Delivery System (melphalan/HDS)
Number of subjects: 91
Study 38704628 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section analysis
Number of subjects: 37
Study 38704628 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage management with intraoperative frozen section analysis
Number of subjects: 37
Study 38704628 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage management
Number of subjects: 37
Study 38704836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension band fixation
Number of subjects: 122
Study 38704836 — intervention group
Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 122
Study 38704840 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadofaragene firadenovec-vncg
Number of subjects: 151
Study 38704861 — intervention group
Group type: EXPERIMENTAL
Intervention: RL-BAV with CoA
Number of subjects: 44
Study 38704861 — intervention group
Group type: COMPARATOR
Intervention: BAV
Number of subjects: 44
Study 38704973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based treatment for perfectionism (ETP)
Number of subjects: 85
Study 38704973 — intervention group
Group type: COMPARATOR
Intervention: Stress management treatment
Number of subjects: 85
Study 38705160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A+I (ibrutinib combined with R-CHOP)
Number of subjects: 870
Study 38705160 — intervention group
Group type: COMPARATOR
Intervention: Group A (R-CHOP with ASCT)
Number of subjects: 870
Study 38705160 — intervention group
Group type: COMPARATOR
Intervention: Group I (ibrutinib only)
Number of subjects: 870
Study 38705160 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A+I (after ASCT)
Number of subjects: 870
Study 38705160 — intervention group
Group type: COMPARATOR
Intervention: Group A (ASCT)
Number of subjects: 870
Study 38705163 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 80
Study 38705163 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with primaquine (0.25 mg/kg)
Number of subjects: 80
Study 38705163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine
Number of subjects: 80
Study 38705163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine (1.66 mg/kg)
Number of subjects: 80
Study 38705167 — intervention group
Group type: EXPERIMENTAL
Intervention: Seralutinib (60 mg twice daily for 2 weeks, then increased to 90 mg twice daily as tolerated)
Number of subjects: 86
Study 38705167 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dry powder inhaler, twice daily for 24 weeks)
Number of subjects: 86
Study 38705225 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision sling (Altis sling, Coloplast)
Number of subjects: 280
Study 38705225 — intervention group
Group type: COMPARATOR
Intervention: Retropubic sling
Number of subjects: 280
Study 38705341 — intervention group
Group type: EXPERIMENTAL
Intervention: Obicetrapib 10 mg
Number of subjects: 2886
Study 38705341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886
Study 38705463 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 65
Study 38705463 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 65
Study 38705488 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body RT
Number of subjects: 48
Study 38705488 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionated intensity-modulated RT
Number of subjects: 48
Study 38705488 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 48
Study 38705489 — intervention group
Group type: EXPERIMENTAL
Intervention: rhSOD enema during CCRT
Number of subjects: 283
Study 38705489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enema)
Number of subjects: 283
Study 38705804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (5 × 10^10 viral particles)
Number of subjects: 0
Study 38705804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (various dose levels)
Number of subjects: 0
Study 38705804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (single dose schedule)
Number of subjects: 0
Study 38705804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38705885 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplo-cord HCT
Number of subjects: 268
Study 38705885 — intervention group
Group type: COMPARATOR
Intervention: Haplo-HCT
Number of subjects: 268
Study 38705907 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroseptal transconjunctival lower blepharoplasty with TTL and ORL release and resected orbital fat grafting
Number of subjects: 40
Study 38705907 — intervention group
Group type: EXPERIMENTAL
Intervention: Global aesthetic improvement scale (GAIS)
Number of subjects: 40
Study 38705907 — intervention group
Group type: EXPERIMENTAL
Intervention: Blepharoplasty outcomes evaluation (BOE)
Number of subjects: 40
Study 38705943 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 139
Study 38706247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadonilimab 10 mg/kg every three weeks (Q3 W) for up to 24 months until progressive disease (PD) or adverse events (AE) discovery.
Number of subjects: 0
Study 38706271 — intervention group
Group type: EXPERIMENTAL
Intervention: Neflamapimod 40mg capsules, twice-a-day (BID) or three-times-a-day (TID), for 16 weeks
Number of subjects: 91
Study 38706271 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 91
Study 38706271 — intervention group
Group type: EXPERIMENTAL
Intervention: Neflamapimod 40mg TID
Number of subjects: 91
Study 38706271 — intervention group
Group type: EXPERIMENTAL
Intervention: Neflamapimod
Number of subjects: 91
Study 38706390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (one intravenous injection)
Number of subjects: 59
Study 38706390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one injection of saline solution)
Number of subjects: 59
Study 38706390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Number of subjects: 59
Study 38706390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 38706592 — intervention group
Group type: EXPERIMENTAL
Intervention: vebreltinib
Number of subjects: 1
Study 38706592 — intervention group
Group type: COMPARATOR
Intervention: tepotinib
Number of subjects: 1
Study 38706610 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB-100 (30-minute infusion on days 4, 6, and 8 at doses of 100 and 140 µg/kg) + tofacitinib (10 mg BID for the first 10 days of the cycle)
Number of subjects: 16
Study 38706610 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB-100 + tofacitinib
Number of subjects: 16
Study 38706611 — intervention group
Group type: EXPERIMENTAL
Intervention: QUS-radiomics model-guided adaptive chemotherapy (experimental arm)
Number of subjects: 60
Study 38706611 — intervention group
Group type: COMPARATOR
Intervention: Standard anthracycline and taxane-based NAC (standard arm)
Number of subjects: 60
Study 38706726 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 Gy salvage radiotherapy (sRT)
Number of subjects: 344
Study 38706726 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy salvage radiotherapy (sRT)
Number of subjects: 344
Study 38706726 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline G3 ED
Number of subjects: 344
Study 38706726 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline G0-2 ED
Number of subjects: 344
Study 38706726 — intervention group
Group type: COMPARATOR
Intervention: Dose intensified sRT (64 Gy vs 70 Gy)
Number of subjects: 344
Study 38707635 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified breast pump suction pattern
Number of subjects: 0
Study 38707635 — intervention group
Group type: COMPARATOR
Intervention: Standard breast pump suction pattern
Number of subjects: 0
Study 38707876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Suspension (LS)
Number of subjects: 73
Study 38707876 — intervention group
Group type: COMPARATOR
Intervention: Sacropexy
Number of subjects: 73
Study 38708017 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnosis program for stress reduction (5 weekly sessions) plus 5 hypnosis audio recordings and an educational booklet on coping with stress
Number of subjects: 47
Study 38708072 — intervention group
Group type: EXPERIMENTAL
Intervention: PWP co-facilitated intervention delivered over six weekly sessions
Number of subjects: 34
Study 38708072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to psychological support)
Number of subjects: 34
Study 38708595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-Seal suture-mediated vascular closure device
Number of subjects: 147
Study 38708601 — intervention group
Group type: EXPERIMENTAL
Intervention: FMF preterm preeclampsia screening test (cutoff of ≥1 in 110)
Number of subjects: 7554
Study 38708601 — intervention group
Group type: COMPARATOR
Intervention: American College of Obstetricians and Gynecologists criteria
Number of subjects: 7554
Study 38708609 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella-supported high-risk PCI
Number of subjects: 1052
Study 38708609 — intervention group
Group type: COMPARATOR
Intervention: Intra Aortic Balloon Pump (IABP)
Number of subjects: 1052
Study 38708880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cold stored platelet transfusion (single apheresis cold stored platelet unit, stored for up to 14 days)
Number of subjects: 0
Study 38708880 — intervention group
Group type: COMPARATOR
Intervention: Standard care resuscitation
Number of subjects: 0
Study 38708880 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cold stored platelet transfusion
Number of subjects: 0
Study 38708959 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pooled, multidonor faecal microbiota transplantation (FMT) for 4 weeks, delivered daily by enema for 2 weeks, followed by every second day for 2 weeks.
Number of subjects: 30
Study 38708959 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pooled, multidonor faecal microbiota transplantation (FMT)
Number of subjects: 30
Study 38708959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 38709006 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir with oral lead-in (OLI)
Number of subjects: 0
Study 38709006 — intervention group
Group type: COMPARATOR
Intervention: Long-acting cabotegravir without oral lead-in (OLI)
Number of subjects: 0
Study 38709212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential dosing of sacituzumab govitecan (SG) followed by talazoparib (TZP)
Number of subjects: 30
Study 38709212 — intervention group
Group type: COMPARATOR
Intervention: Concurrent dosing of sacituzumab govitecan (SG) with talazoparib (TZP)
Number of subjects: 30
Study 38709215 — intervention group
Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 214
Study 38709215 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 214
Study 38709220 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v 10 mg plus atezolizumab 1,200 mg intravenously every 3 weeks
Number of subjects: 34
Study 38709220 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v weekly for 4 weeks and then every 2 weeks plus atezolizumab 840 mg intravenously every 2 weeks
Number of subjects: 34
Study 38709220 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP-IL2v plus atezolizumab
Number of subjects: 34
Study 38709228 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIT-101 (low dose)
Number of subjects: 14
Study 38709228 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIT-101 (intermediate dose)
Number of subjects: 14
Study 38709228 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIT-101 (high dose)
Number of subjects: 14
Study 38709329 — intervention group
Group type: EXPERIMENTAL
Intervention: PostpartumCare.ca (web-enabled psychoeducational resource) for four weeks
Number of subjects: 103
Study 38709329 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 103
Study 38709456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative haemoadsorption for antithrombotic drug removal during cardiac surgery
Number of subjects: 0
Study 38709500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisinicline, 3 mg, taken 3 times daily (n=107)
Number of subjects: 160
Study 38709500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 160
Study 38709509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk order for mammogram
Number of subjects: 24632
Study 38709509 — intervention group
Group type: COMPARATOR
Intervention: No order
Number of subjects: 24632
Study 38709509 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 24632
Study 38709509 — intervention group
Group type: COMPARATOR
Intervention: No text message reminders
Number of subjects: 24632
Study 38709509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician endorsement
Number of subjects: 24632
Study 38709509 — intervention group
Group type: COMPARATOR
Intervention: Standard messaging
Number of subjects: 24632
Study 38709535 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (n=34)
Number of subjects: 101
Study 38709535 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour hypothermia (33.5 °C) (n=31)
Number of subjects: 101
Study 38709535 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour hypothermia (33.5 °C) (n=36)
Number of subjects: 101
Study 38709535 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 101
Study 38709534 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 30
Study 38709534 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 38709550 — intervention group
Group type: EXPERIMENTAL
Intervention: Comunică intervention (8 live text-based counseling sessions on a mobile platform)
Number of subjects: 305
Study 38709550 — intervention group
Group type: COMPARATOR
Intervention: Content-matched education attention control (8 time-matched educational modules)
Number of subjects: 305
Study 38709554 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) scenario
Number of subjects: 100
Study 38709554 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic intervention (educational video)
Number of subjects: 100
Study 38709554 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device for continuous data collection
Number of subjects: 100
Study 38709554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-post comparison analysis
Number of subjects: 100
Study 38709554 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning for personal digital phenotype profile
Number of subjects: 100
Study 38709654 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlimb coordination
Number of subjects: 56
Study 38709654 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal symmetry
Number of subjects: 56